CLINICAL RESEARCH: CLINICAL TRIALS
Acute Myocardial Infarction With Hyperoxemic Therapy (AMIHOT)A Prospective, Randomized Trial of Intracoronary Hyperoxemic Reperfusion After Percutaneous Coronary Intervention
William W. O'Neill, MD*,*,
Jack L. Martin, MD ,
Simon R. Dixon, MBChB ,
Antonio L. Bartorelli, MD ,
Daniela Trabattoni, MD ,
Pranobe V. Oemrawsingh, MD||,
Douwe E. Atsma, MD||,
Michael Chang, MD¶,
William Marquardt, MD¶,
Jae K. Oh, MD#,
Mitchell W. Krucoff, MD**,
Raymond J. Gibbons, MD#,
J. Richard Spears, MD AMIHOT Investigators
* University of Miami, Miami, Florida
Sharpe-Strumia Research Foundation of the Bryn Mawr Hospital, Main Line Health System, Bryn Mawr, Pennsylvania
William Beaumont Hospital, Royal Oak, Michigan
Centro Cardiologico Monzino, University of Milan, Milan, Italy
|| Leiden University Medical Center, Leiden, the Netherlands
¶ Mercy General Hospital, Sacramento, California
# Mayo Clinic, Rochester, Minnesota
** Duke Clinical Research Institute, Durham, North Carolina
 Wayne State University, Detroit, Michigan
Manuscript received December 22, 2005;
revised manuscript received December 22, 2006,
accepted January 2, 2007.
* Reprint requests and correspondence: Dr. William W. O'Neill, Leonard M. Miller School of Medicine, University of Miami, P.O. Box 016099 (R.699), Miami, Florida 33101. (Email: woneill{at}med.miami.edu).
Objectives: This study sought to determine whether hyperoxemic reperfusion with aqueous oxygen (AO) improves recovery of ventricular function after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
Background: Hyperbaric oxygen reduces myocardial injury and improves ventricular function when administered during ischemia-reperfusion.
Methods: In a prospective, multicenter study, 269 patients with acute anterior or large inferior AMI undergoing primary or rescue PCI (<24 h from symptom onset) were randomly assigned after successful PCI to receive hyperoxemic reperfusion (treatment group) or normoxemic blood autoreperfusion (control group). Hyperoxemic reperfusion was performed for 90 min using intracoronary AO. The primary end points were final infarct size at 14 days, ST-segment resolution, and regional wall motion score index of the infarct zone at 3 months.
Results: At 30 days, the incidence of major adverse cardiac events was similar between the control and AO groups (5.2% vs. 6.7%, p = 0.62). There was no significant difference in the incidence of the primary end points between the study groups. In post-hoc analysis, anterior AMI patients reperfused <6 h who were treated with AO had a greater improvement in regional wall motion ( wall motion score index = 0.54 in control group vs. 0.75 in AO group, p = 0.03), smaller infarct size (23% of left ventricle in control group vs. 9% of left ventricle in AO group, p = 0.04), and improved ST-segment resolution compared with normoxemic controls.
Conclusions: Intracoronary hyperoxemic reperfusion was safe and well tolerated after PCI for AMI, but did not improve regional wall motion, ST-segment resolution, or final infarct size. A possible treatment effect was observed in anterior AMI patients reperfused <6 h of symptom onset.
|
Abbreviations and Acronyms
| | AMI = acute myocardial infarction | | AO = aqueous oxygen | | PCI = percutaneous coronary intervention | | RWMSI = regional wall motion score index | | TIMI = Thrombolysis In Myocardial Infarction |
|
Related Articles
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A28.
[Full Text]
[PDF]
-
The Search for Myocardial Protection: Is There Still Hope?
- Christopher B. Granger and Manesh R. Patel
J. Am. Coll. Cardiol. 2007 50: 406-408.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. R. Patel, R. W. Smalling, H. Thiele, H. X. Barnhart, Y. Zhou, P. Chandra, D. Chew, M. Cohen, J. French, D. Perera, et al.
Intra-aortic Balloon Counterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock: The CRISP AMI Randomized Trial
JAMA,
September 28, 2011;
306(12):
1329 - 1337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Kloner and L. Schwartz Longacre
State of the Science of Cardioprotection: Challenges and Opportunities-- Proceedings of the 2010 NHLBI Workshop on Cardioprotection
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2011;
16(3-4):
223 - 232.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Gibbons
Tc-99m SPECT Sestamibi for the Measurement of Infarct Size
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2011;
16(3-4):
321 - 331.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mewton and K. Yoneyama
No current evidence that routine administration of oxygen to people with acute myocardial infarction improves pain or mortality; further conclusive trials are needed
Evid. Based Med.,
December 1, 2010;
15(6):
178 - 179.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Prasad, G. W. Stone, D. R. Holmes, and B. Gersh
Reperfusion Injury, Microvascular Dysfunction, and Cardioprotection: The "Dark Side" of Reperfusion
Circulation,
November 24, 2009;
120(21):
2105 - 2112.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. W. Stone, J. L. Martin, M.-J. de Boer, M. Margheri, E. Bramucci, J. C. Blankenship, D. C. Metzger, R. J. Gibbons, B. S. Lindsay, B. H. Weiner, et al.
Effect of Supersaturated Oxygen Delivery on Infarct Size After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Circ Cardiovasc Interv,
October 1, 2009;
2(5):
366 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sezer, A. Cimen, E. Aslanger, A. Elitok, B. Umman, Z. Bugra, E. Yormaz, C. Turkmen, I.s. Adalet, Y. Nisanci, et al.
Effect of Intracoronary Streptokinase Administered Immediately After Primary Percutaneous Coronary Intervention on Long-Term Left Ventricular Infarct Size, Volumes, and Function
J. Am. Coll. Cardiol.,
September 15, 2009;
54(12):
1065 - 1071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Hausenloy and D. Yellon
Chapter 11 Novel Cardioprotective Strategies
Cardiac Protection,
January 1, 2009;
1(1):
med-9780199544769-chapter - med-9780199544769-chapter.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
G. W. Stone
Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions
Circulation,
July 29, 2008;
118(5):
552 - 566.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al.
Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
JAMA,
April 16, 2008;
299(15):
1788 - 1799.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Thibault, C. Piot, P. Staat, L. Bontemps, C. Sportouch, G. Rioufol, T. T. Cung, E. Bonnefoy, D. Angoulvant, J.-F. Aupetit, et al.
Long-Term Benefit of Postconditioning
Circulation,
February 26, 2008;
117(8):
1037 - 1044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Direct Inhibition of {delta}-Protein Kinase C Enzy
Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction
Circulation,
February 19, 2008;
117(7):
886 - 896.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. B. Granger and M. R. Patel
The Search for Myocardial Protection: Is There Still Hope?
J. Am. Coll. Cardiol.,
July 31, 2007;
50(5):
406 - 408.
[Full Text]
[PDF]
|
 |
|
|